PNTG insider filings
Pennant Group, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen PNTG transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 10 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 218 shares, $8,098 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 218 shares @ $37.15 ($8,098) by Steik Jason Paul, filed 2026-11-19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Steik Jason Paul — Chief Clinical Officer | 1 | — | 1 leg · 218 sh · $8,098 | — |
| Gochnour John J — Chief Operating Officer | 1 | — | — | 3 |
| SMITH BARRY M — Director | 2 | — | — | 2 |
| COVEY STEPHEN M R — Director | 1 | — | — | 1 |
| Christensen Christopher R. — Director | 1 | — | — | 1 |
| Lamb Scott E — Director | 1 | — | — | 1 |
| Morris Gregory K Sr. — Director | 1 | — | — | 1 |
| Nackel John G. — Director | 1 | — | — | 1 |
| Snapper Suzanne D. — Director | 1 | — | — | 1 |
Recent insider filings — Pennant Group, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Steik Jason Paul — Chief Clinical Officer | Sale (S): 218 @ $37.15 | EDGAR |
| 2026-11-13 | 4 | SMITH BARRY M — Director | Gift (G): 5,100 @ $36.74 | EDGAR |
| 2026-10-27 | 4 | Gochnour John J — Chief Operating Officer | Option exercise (M): 5,948 @ $6.10 · Tax withholding (F): 6,624 @ $42.05 · Option exercise (M): 5,948 (derivative) @ $6.10 | EDGAR |
| 2026-10-19 | 4 | Morris Gregory K Sr. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-10-19 | 4 | COVEY STEPHEN M R — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-10-19 | 4 | Lamb Scott E — Director | Grant/award (A): 2,400 @ $0 | EDGAR |
| 2026-10-19 | 4 | SMITH BARRY M — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-10-19 | 4 | Snapper Suzanne D. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-10-19 | 4 | Christensen Christopher R. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-10-19 | 4 | Nackel John G. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-08-10 | 4 | Steik Jason Paul — Chief Clinical Officer | Sale (S): 1,394 @ $38.52 | EDGAR |
| 2026-08-10 | 4 | Guerisoli Brent — Chief Executive Officer | Sale (S): 4,285 @ $38.52 | EDGAR |
| 2026-08-10 | 4 | Cheney Kirk Sterling — EVP, GC and Corp Secy | Sale (S): 1,393 @ $38.52 | EDGAR |
| 2026-07-17 | 4 | Morris Gregory K Sr. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-07-17 | 4 | Snapper Suzanne D. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-07-17 | 4 | Nackel John G. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-07-17 | 4 | Christensen Christopher R. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-07-17 | 4 | Lamb Scott E — Director | Grant/award (A): 2,400 @ $0 | EDGAR |
| 2026-07-17 | 4 | SMITH BARRY M — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-07-17 | 4 | COVEY STEPHEN M R — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-07-14 | 4 | Guerisoli Brent — Chief Executive Officer | Option exercise (M): 6,248 @ $4.54 · Sale (S): 3,159 @ $41.56 · Option exercise (M): 6,248 (derivative) @ $4.54 | EDGAR |
| 2026-07-09 | 4 | Guerisoli Brent — Chief Executive Officer | Option exercise (M): 6,249 @ $4.54 · Sale (S): 3,165 @ $40.51 · Option exercise (M): 6,249 (derivative) @ $4.54 | EDGAR |
| 2026-05-27 | 4 | Guerisoli Brent — Chief Executive Officer | Option exercise (M): 4,463 @ $3.84 · Sale (S): 22 @ $34.86 · Sale (S): 2,032 @ $35.08 · Sale (S): 200 @ $35.10 · Option exercise (M): 4,463 @ $3.84 · Sale (S): 2,254 @ $35.08 · +2 more | EDGAR |
| 2026-04-17 | 4 | Morris Gregory K Sr. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-04-17 | 4/A | Gochnour John J — Chief Operating Officer | Grant/award (A): 11,214 @ $0 · Grant/award (A): 41,000 (derivative) @ $33.30 | EDGAR |
| 2026-04-17 | 4/A | Guerisoli Brent — Chief Executive Officer | Grant/award (A): 11,260 @ $0 · Grant/award (A): 45,000 (derivative) @ $33.30 | EDGAR |
| 2026-04-17 | 4/A | Cheney Kirk Sterling — EVP, GC and Corp Secy | Grant/award (A): 2,874 @ $0 · Grant/award (A): 30,000 (derivative) @ $33.30 | EDGAR |
| 2026-04-17 | 4/A | Walbom Lynette — Chief Financial Officer | Grant/award (A): 8,025 @ $0 · Grant/award (A): 34,000 (derivative) @ $33.30 | EDGAR |
| 2026-04-17 | 4 | Snapper Suzanne D. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-04-17 | 4 | Nackel John G. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-04-17 | 4 | Christensen Christopher R. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-04-17 | 4 | Lamb Scott E — Director | Grant/award (A): 2,400 @ $0 | EDGAR |
| 2026-04-17 | 4 | SMITH BARRY M — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-04-17 | 4 | COVEY STEPHEN M R — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-03-12 | 4 | Cheney Kirk Sterling — EVP, GC and Corp Secy | Grant/award (A): 4,085 @ $0 · Grant/award (A): 30,000 (derivative) @ $33.30 | EDGAR |
| 2026-03-12 | 4 | Gochnour John J — Chief Operating Officer | Grant/award (A): 18,565 @ $0 · Grant/award (A): 41,000 (derivative) @ $33.30 | EDGAR |
| 2026-03-12 | 4 | Walbom Lynette — Chief Financial Officer | Grant/award (A): 14,292 @ $0 · Grant/award (A): 34,000 (derivative) @ $33.30 | EDGAR |
| 2026-03-12 | 4 | Steik Jason Paul — Chief Clinical Officer | Grant/award (A): 26,000 (derivative) @ $33.30 | EDGAR |
| 2026-03-12 | 4 | Guerisoli Brent — Chief Executive Officer | Grant/award (A): 20,052 @ $0 · Grant/award (A): 45,000 (derivative) @ $33.30 | EDGAR |
| 2026-01-21 | 4 | Morris Gregory K Sr. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-01-21 | 4 | Snapper Suzanne D. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-01-21 | 4 | Nackel John G. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-01-21 | 4 | Christensen Christopher R. — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-01-21 | 4 | Lamb Scott E — Director | Grant/award (A): 2,400 @ $0 | EDGAR |
| 2026-01-21 | 4 | SMITH BARRY M — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2026-01-21 | 4 | COVEY STEPHEN M R — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2025-11-13 | 4 | Cheney Kirk Sterling — EVP, GC and Corp Secy | Option exercise (M): 3,800 @ $15.09 · Option exercise (M): 3,800 (derivative) | EDGAR |
| 2025-10-16 | 4 | Lamb Scott E — Director | Grant/award (A): 2,400 @ $0 | EDGAR |
| 2025-10-16 | 4 | SMITH BARRY M — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
| 2025-10-16 | 4 | COVEY STEPHEN M R — Director | Grant/award (A): 1,900 @ $0 | EDGAR |
Recent 8-K events — Pennant Group, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-17 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-02 | 8-K/A | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-02 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PNTG returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs